Every material Form 8-K HERON THERAPEUTICS, INC. /DE/ has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Heron Therapeutics reported third-quarter 2026 net revenue of $35.3 million, down 7.8% from $38.2 million a year earlier, while its net loss narrowed to $5.0 million from $17.5 million. The same day, Heron agreed to sell substantially all of its assets to CorMedix Therapeutics, a deal that requires Heron stockholder approval, and the company is not providing 2026 financial guidance.
Q3 2026 net revenue was $35.3 million, compared with $38.2 million in Q3 2025 and $37.7 million in Q2 2026.
Q3 2026 net loss was $5.0 million, compared with $17.5 million in Q3 2025.
CorMedix Therapeutics will acquire substantially all of Heron's assets under a definitive asset purchase agreement, subject to Heron stockholder approval and other closing conditions.
Heron withdrew its full-year 2026 guidance in August 2026 and is not providing guidance at this time; cash and short-term investments were $23.4 million at September 30, 2026.
Heron Therapeutics agreed on November 8, 2026 to sell substantially all of its assets to CorMedix, with Heron keeping its tax loss carryforwards, cash and CorMedix shares, and exiting its current operations. The deal requires Heron stockholder approval and is expected to close in the first quarter of 2027, and shareholders will hold a company that no longer runs its current business.
Upfront consideration of $145.0 million in cash, subject to adjustments, plus 14,583,333 CorMedix common shares
Up to $55 million in earn-out payments tied to 2028 ZYNRELEF net sales, plus a 5% royalty on certain product sales above $25.0 million in 2027 through 2029
Proceeds will repay all amounts outstanding under the Hercules working capital facility, and Rubric's $35.0 million of convertible notes will be exchanged for CorMedix shares
Requires approval by holders of a majority of Heron common stock; $4.0 million termination fee payable in specified circumstances; expected close in the first quarter of 2027
Heron Therapeutics entered a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services on September 23, 2026. The deal gives Heron an exclusive, sublicensable license to import, distribute, sell and market certain products in the United States and its territories, plus a non-exclusive manufacturing license worldwide for sales in that territory. The filing does not disclose any upfront payment, milestone amounts or royalty rates, so its financial size for shareholders cannot be determined from this document.
Agreement dated September 23, 2026 with Long Grove Pharmaceuticals, LLC; Capstone Development Services Company, LLC is a party solely for exclusivity covenants and backstop obligations
Heron must pay Long Grove regulatory milestones, sales-based milestones and royalties, and be reimbursed for certain expenses; amounts are not stated
Initial term of 10 years from first commercial sale, with automatic 2-year renewals; either party may terminate on certain customary conditions
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026
Heron Therapeutics amended its Tax Benefit Preservation Plan, a shareholder rights arrangement generally designed to protect the company's tax attributes, extending its Final Expiration Date from August 14, 2026 to August 14, 2029. The filing does not describe a change in the company's financial results or operations, but the extension changes the length of the plan that shareholder rights are tied to.
Amendment No. 1 was entered into on August 13, 2026, with Computershare Trust Company, N.A. as rights agent.
The Final Expiration Date of the original plan, dated August 14, 2025, moves from August 14, 2026 to August 14, 2029.
The amendment is filed as Exhibit 4.1 and is incorporated into Item 3.03 as a material modification to rights of security holders.
Heron Therapeutics reported second-quarter 2026 net revenue of $37.7 million, up 1.3% from a year earlier, while its net loss widened to $5.5 million from $2.4 million. The company withdrew its full-year 2026 net product sales and Adjusted EBITDA guidance after a June 2026 court decision on CINVANTI patents made the timing of potential generic entry hard to forecast, and it said it is considering strategic alternatives with no timetable set.
Q2 2026 net revenue was $37.7 million, up 1.3% from $37.2 million in Q2 2025; CINVANTI revenue fell 9.7% to $21.8 million.
Q2 2026 net loss was $5.5 million, or $0.03 per share, compared with a net loss of $2.4 million, or $0.02 per share, a year earlier.
Full-year 2026 guidance was withdrawn, citing the June 2026 U.S. District Court for the District of Delaware decision on CINVANTI patents.
Cash, cash equivalents and short-term investments totaled $42.7 million at June 30, 2026; the Hercules Capital credit facility was amended with a $13.5 million principal reduction at execution.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HERON THERAPEUTICS, INC. /DE/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →